Drug intelligence / Profile preview

T3P-1017

Development stage: Preclinical
Lead developer: Boehringer Ingelheim
Modality: Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Recombinant Proteins and Enzymes, Live Biotherapeutic Products → Microbiome Therapeutics

Overview

T3P-1017 is a preclinical drug candidate developed by T3 Pharmaceuticals AG for the treatment of neoplasms (cancer). It leverages a bacterial delivery platform that utilizes live engineered *Yersinia enterocolitica* bacteria. This platform is designed to deliver bioactive proteins directly to cancerous cells and their surrounding tumor micro-environments. The aim is to modulate the tumor microenvironment, stimulate an immune response, and potentially convert immunologically "cold" tumors into "hot" ones, thereby enhancing the efficacy of immunotherapy for a broader range of cancer patients.

Beyond the preview

Go deeper on T3P-1017.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on T3P-1017.

Explore the full profile